Experimental cancer drug WTX212A enters first human tests
NCT ID NCT07269899
First seen Dec 08, 2025 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This early-phase study is testing an experimental drug called WTX212A, given alone or after radiation therapy, in 12 people with advanced solid tumors. The main goal is to see if the drug is safe and whether it can shrink tumors. Because this is a phase 1 trial, it is very small and focused on safety, not proof of a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Center of SUN YAT-senU
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cancer center of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510060, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
WTX212A (erythrocyte-αPD-1 antibody conjugate) and radiotherapy
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that are hard to treat.
What could go wrong
This is a very early phase 1 trial with only 12 participants, so it is too small to prove effectiveness. The treatment may not shrink tumors or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.